Research Paper on ArcticZymes R2D Ligase[TM] is published in the Biotechnology Journal

Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase^TM is published in the Biotechnology Journal

ArcticZymes Technologies ASA is pleased to announce the release of a research paper in the international peer-reviewed publication, Biotechnology Journal, showcasing the features and potential of the patent pending ArcticZymes R2D Ligase^TM. This novel enzyme, introduced in 2021, has functionalities enabling innovative advancements in RNA analysis, diagnostics and synthesis.

Authored by Sigurd Gundesø et al., the recent publication entitled "R2D Ligase: Unveiling a Novel DNA Ligase with Surprising DNA-to-RNA Ligation Activity" describes the uniqueness of the ArcticZymes R2D Ligase^TM and its specificity and ability to ligate and bridge DNA-to-RNA.

Through dissemination of our research findings in  peer-reviewed journals, ArcticZymes aims to elevate awareness of our cutting-edge products and stimulate the emergence of disruptive technologies. We are committed to driving forward progress in the field, catalyzing innovation and paving the way for impactful scientific breakthroughs.

Michael Akoh, CEO comments: "We are happy to see the publication of our research paper on AZ R2D Ligase^TM in the Biotechnology Journal. This marks a milestone for ArcticZymes and underscores the innovative potential of our ArcticZymes R2D Ligase^TM. The insights shared in this publication highlight our commitment to advancing biotechnology and driving meaningful progress in the field of molecular biology. We are excited about the possibilities this enzyme presents and look forward to further contributing to discoveries in RNA diagnostics and synthesis."

Access the published article via this link: http://dx.doi.org/10.1002/biot.202300711

For more information, please contact:  

ir@arcticzymes.com  

About ArcticZymes Technologies ASA   

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.  

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.  

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.   

For more information, please visit the website: www.arcticzymes.com  

http://publish.ne.cision.com//Release/ViewReleaseHtml/2E7745C1E618CFABE0C856B0705FC7D6

https://mb.cision.com/Public/1090/3953110/be3a56ec5b3c01e1.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English